Targacept, Inc. is a biopharmaceutical company advancing NNR Therapeutics™ for the treatment of various diseases and disorders. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.
Gastroparesis is a chronic and debilitating disorder affecting a significant number of patients with diabetes. READ MORE about our development plans for TC-6499 in this indication.
Targacept has assembled a dedicated team with years of experience in pharmaceutical development. READ MORE about our culture and aspirations.